Transcriptional down-regulation of the platelet ADP receptor P2Y12 and clusterin in patients with systemic lupus erythematosus

Journal of Thrombosis and Haemostasis

Volumn 2, Issue 8, 2004, Pages 1436-1442

  Wang, L ^a   Erling, P ^a   Bengtsson, A A ^a   Truedsson, L ^a   Sturfelt, G ^a   Erlinge, David ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Clusterin; P2 receptor; Platelets; Systemic lupus erythematosus

Indexed keywords

ADENOSINE DIPHOSPHATE; CLUSTERIN; MESSENGER RNA; PURINE P2X1 RECEPTOR; PURINE P2Y1 RECEPTOR; PURINE P2Y12 RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; RNA ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

ADOLESCENT; ADULT; BLOOD PLATELETS; BLOTTING, WESTERN; CLUSTERIN; DIMERIZATION; DOWN-REGULATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; GLYCOPROTEINS; HUMANS; LINEAR MODELS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MOLECULAR CHAPERONES; PLATELET ACTIVATION; PLATELET AGGREGATION; RECEPTORS, PURINERGIC P2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; RNA, MESSENGER; TICLOPIDINE;

EID: 13244284598     PISSN: 15387933     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2004.00854.x     Document Type: Article

References (36)

1. Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 338-46.
2. Bacon PA, Stevens RJ, Carruthers DM, Young SP, Kitas GD. Accelerated atherogenesis in autoimmune rheumatic diseases. Autoimmun Rev 2002; 1: 338-47.
3. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, D'Agostino RB, Kuller LH. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997; 145: 408-15.
4. Joseph JE, Harrison P, Mackie IJ, Isenberg J. Machin J. Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Br J Haematol 2001; 115 451-9.
5. Nojima J, Suehisa E, Kuratsune H, Machii T, Koike T, Kitani T, Kanakura Y, Amino N. Platelet activation induced by combined effects of anticardiolipin and lupus anticoagulant IgG antibodies in patients with systemic lupus erythematosus - possible association with thrombotic and thrombocytopenic complications. Thromb Haemost 1999; 81: 436-41.
6. Nojima J, Kuratsune H, Suehisa E, Kawasaki T, Machii T, Kitani T, Iwatani Y, Kanakura Y. Acquired activated protein C resistance is associated with the co-existence of anti-prothrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus. Br J Haematol 2002; 118: 577-83.
7. Kunapuli SP. Multiple P2 receptor subtypes on platelets: a new interpretation of their function. Trends Pharmacol Sci 1998; 19: 391-4.
8. Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny JL, Aiach M, Gaussem P. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003; 108: 989-95.
9. Paul BZ, Vilaire G, Kunapuli SP, Bennett JS. Concurrent signaling from Galphaq- and Galphai-coupled pathways is essential for agonist-induced alphavbeta3 activation on human platelets. J Thromb Haemost 2003; 1: 814-20.
10. CAPRIE. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329-39.
11. Gachet C. Platelet activation by ADP. the role of ADP antagonists. Ann Med 2000; 32 (Suppl. 1): 15-20.
12. Rosenberg ME, Silkensen J. Clusterin: physiologic and pathophysiologic considerations. Int J Biochem Cell Biol 1995; 27: 633-45.
13. Tschopp J, French LE. Clusterin: modulation of complement function. Clin Exp Immunol 1994; 97 (Suppl. 2): 11-4.
14. Walport MJ, Davies KA, Morley BJ, Botto M. Complement deficiency and autoimmunity. Ann N Y Acad Sci 1997; 815: 267-81.
15. Andrade F, Casciola-Rosen L, Rosen A. Apoptosis in systemic lupus erythematosus. Clinical implications. Rheum Dis Clin North Am 2000; 26: 215-27, v.
16. Newkirk MM, Apostolakos P, Neville C, Fortin PR. Systemic lupus erythematosus, a disease associated with low levels of clusterin/apoJ, an antiinflammatory protein. J Rheumatol 1999; 26: 597-603.
17. Gnatenko DV, Dunn JJ, McCorkle SR, Weissmann D, Perrotta PL, Bahou WF. Transcript profiling of human platelets using microarray and serial analysis of gene expression. Blood 2003; 101: 2285-93.
18. Wang L, Östberg O, Wihlborg AK, Brogren H, Jern S, Erlinge D. Quantification of ADP and ATP Receptor Expression in Human Platelets. J Thromb Haemost 2003; 1: 330-6.
19. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
20. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29 288-91.
21. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-40.
22. Wang L, Karlsson L, Moses S, Hultgårdh-Nilsson A, Andersson M, Borna C, Gudbjartsson T, Jern S, Erlinge D. P2 Receptor Profiles in Human Vascular Smooth Muscle and Endothelial Cells. J Cardiovasc Pharmacol 2002; 40: 841-53.
23. Borna C, Wang L, Gudbjartsson T, Karlsson L, Jern S, Malmsjo M, Erlinge D. Contractions in human coronary bypass vessels stimulated by extracellular nucleotides. Ann Thorac Surg 2003; 76: 50-7.
24. Wang L, Andersson M, Karlsson L, Watson MA, Cousens DJ, Jern S, Erlinge D. Increased mitogenic and decreased contractile P2 receptors in smooth muscle cells by shear stress in human vessels with intact endothelium. Arterioscler Thromb Vasc Biol 2003; 23: 1370-6.
25. Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an in vitro platelet function analyzer - PFA-100. Semin Thromb Hemost 1995; 21: 106-12.
26. Kirszbaum L, Sharpe JA, Murphy B, d'Apice AJ, Classon B, Hudson P, Walker ID. Molecular cloning and characterization of the novel, human complement-associated protein, SP-40,40. a link between the complement and reproductive systems. Embo J 1989; 8: 711-8.
27. Bach UC, Baiersdorfer M, Klock G, Cattaruzza M, Post A, Koch-Brandt C. Apoptotic cell debris and phosphatidylserine-containing lipid vesicles induce apolipoprotein J (clusterin) gene expression in vital fibroblasts. Exp Cell Res 2001; 265: 11-20.
28. Lu L, Wang LS, Cooper RJ, Liu HJ, Turner K, Weich N, Broxmeyer HE. Suppressive effects of TNF-alpha, TGF-beta1, and chemokines on megakaryocytic colony formation in CD34+ cells derived from umbilical cord blood compared with mobilized peripheral blood and bone marrow. J Hematother Stem Cell Res 2000; 9: 195-204.
29. Hechler B, Toselli P, Ravanat C, Gachet C, Ravid K. Mpl ligand increases P2Y1 receptor gene expression in megakaryocytes with no concomitant change in platelet response to ADP. Mol Pharmacol 2001; 60: 1112-20.
30. Wang Q, Miyakawa Y, Fox N, Kaushansky K. Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. Blood 2000; 96: 2093-9.
31. Kato K, Kamezaki K, Shimoda K, Numata A, Haro T, Aoki K, Ishikawa F, Takase K, Ariyama H, Matsuda T, Miyamoto T, Nagafuji K, Gondo H, Nakayama K, Harada M. Intracellular signal transduction of interferon on the suppression of haematopoietic progenitor cell growth. Br J Haematol 2003; 123: 528-35.
32. Ronnblom L, Alm GV. Systemic lupus erythematosus and the type I interferon system. Arthritis Res Ther 2003; 5: 68-75.
33. Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H, Ronnblom L. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000; 9: 664-71.
34. Crow MK. Interferon-alpha: a new target for therapy in systemic lupus erythematosus? Arthritis Rheum 2003; 48: 2396-401.
35. Blomberg S, Eloranta ML, Magnusson M, Alm GV, Ronnblom L. Expression of the markers BDCA-2 and BDCA-4 and production of interferon-alpha by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Rheum 2003; 48: 2524-32.
36. Jimenez S, Cervera R, Font J, Ingelmo M. The epidemiology of systemic lupus erythematosus. Clin Rev Allergy Immunol 2003; 25 3-12.